Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Seattle Genetics, Inc. (NASDAQ:SGEN), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Alkermes Plc (NASDAQ:ALKS), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Seattle Genetics, Inc. (NASDAQ:SGEN) slipped -3.62% and closed at $46.00 in the last trading session with the overall traded volume of 1.61 million shares, more versus the average volume of 657,330 shares. Its 52 weeks high price was $49.23 and suffered lowest price of $21.05 in the same period.
It has market cap of $5.60 billion while its total outstanding shares are 121.84 million. Its stock’s 3 months performance stands at +48.34%. Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer.
Will SGEN Get Buyers Even After The Recent Rally? Find Out Here
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined -1.61% with the closing price of $104.41. The overall volume in the last trading session was 1.45 million shares. Its fifty two week range was $52.50-$106.98. The total market capitalization remained $34.75 billion.
The stock gained +77.36% in this year and reported the increase of +5.25% in the last 5 days. In its share capital, the company has 332.87 million outstanding shares. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics.
Has VRX Found The Bottom and Ready To Move Up? Find Out Here
Alkermes Plc (NASDAQ:ALKS) decreased -0.29% to close at $35.09 in the last trading session and its total traded volume was 1.49 million shares, beating the average volume of 674,088. The company has market cap of $4.76 billion.
The stock has positive year-to-date performance of +89.47% while its quarterly performance remained +29.99%. Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes.
Why Should Investors Buy ALKS After the Recent Fall? Just Go Here and Find Out
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined -0.33% to closed at $113.65 and its overall volume in the last trading session was 1.46 million shares, beating the average volume of 743,912. It has market cap of $22.23 billion while its total outstanding shares are 195.56 million.
The stock gained +23.05% in this year and reported the loss of -0.43% in the last 5 days. Its 3 months performance stands at +28.46%. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products.
Has ALXN Found The Bottom And Ready To Gain Momentum? Find Out Here
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)